🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 87164F105
- Market Cap
- Small Cap · $209 Million
- IPO
- 3/2/2016 · $12.00/share
Business: Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer. Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors.
Notes: S
Company Contact
- CEO
- Briggs W. Morrison, M.D.
- CFO
- Allan L. Shaw
- Headquarters
- 400 Totten Pond Road, Suite 110, Waltham, MA 02451
- Phone
- 781-419-1400
- Investor Relations
- Barbara Ryan · 203-274-2825 · bryan@syndax.com